Going ahead, improving domestic volumes, rising chronic contribution and sustained export momentum are expected to support growth. Mankind Pharma targets 1.1–1.2x IPM outperformance over the next two quarters and double-digit export growth in FY27. Consumer Healthcare remains a key monitorable, with high-single-digit growth expected in FY27 and recovery anticipated in FY28. Management retained FY27 Ebitda margin guidance of 25.5–26.5%, with research and development spend at 2.8–3.0% of revenue.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Report
Following Mankind Pharma Ltd.'s September-quarter results, the brokerage Systematix has tweaked its estimates and maintain Hold rating with a target price of Rs 2,498, based on 35 times FY28E earnings per share. The brokerage expects revenue/Ebitda/profit after tax compound annual growth rate of 14%/15.2%/24.5% over FY26–FY28E.revenue (Rs 43,379 million) grew 17.3% YoY, exceeding brokerage's estimates and consensus by 3.4% and 4.3%, respectively.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
PAT (Rs 7,115 mn) grew 37.7% YoY, exceeding Systematix' estimate and consensus by 5.5% and 15.7%, respectively, with PAT margin of 16.4%, 32 bps above estimates, supported by lower finance costs and lower ETR.
ALSO READ | Urban Company: Motilal Oswal Upgrades Rating To 'Buy' As Core Business Gains Momentum; Check Target Price
Revenue beat was primarily led by export formulations (33% YoY), partially offset by weakness in consumer business (flat YoY).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
